BPC157.now
About BPC157.now

Independent editorial coverage. No sales. No prescriptions.

BPC157.now exists to cover one thing well: the formal FDA regulatory process around BPC-157. With a scheduled Pharmacy Compounding Advisory Committee (PCAC) hearing on July 23, 2026, there has never been a more important moment to separate regulatory signal from marketing noise.

Why BPC157.now exists

The online conversation about BPC-157 is dominated by two forces: vendors trying to sell it and advocates trying to build access. Both have interests that can distort the information environment. Consumers researching the substance — especially those with genuine health questions — deserve a resource that is interested only in what the record actually says.

We are that resource. We translate formal regulatory developments into plain language, publish as close to the source as possible, and correct ourselves when we get something wrong. We do not have an opinion on whether BPC-157 should or should not be on the 503A bulks list. That is the FDA's call to make. Our job is to help people understand what the FDA is actually saying.

What we cover

  • PCAC briefing documents — when they become public, we summarize them in plain English within 24 hours.
  • FDA rulemaking — notices of proposed rulemaking, public comment periods, and final rules related to BPC-157 compounding status.
  • Research context — editorial overviews of the published literature, with honest characterization of evidence quality and gaps.
  • Regulatory explainers — how 503A works, what a PCAC recommendation means, what happens next in the process.

What we do not cover

  • Vendor product reviews or comparisons
  • Dosing advice or protocols
  • Testimonials or anecdotal reports
  • Content designed to facilitate access to BPC-157

Our limitations

We are an editorial team, not a medical or legal team. Nothing on this site constitutes medical advice, legal advice, or investment advice. Regulatory status can change, and we may lag breaking developments by hours. For health decisions, consult a licensed healthcare professional. For legal questions about regulatory status, consult a regulatory attorney.

Editorial standards

Five things we commit to

Editorial independence

BPC157.now has no financial relationship with any vendor, compounding pharmacy, telehealth clinic, or anyone who sells, distributes, or promotes BPC-157 or related products. We accept no advertising from the peptide or wellness supplement industry. Our editorial decisions are not influenced by commercial interests.

Regulatory accuracy first

We cover the formal regulatory record — what the FDA publishes, what the PCAC recommends, what rulemaking says. We don't amplify social-media claims, vendor marketing, or anecdote. Every regulatory statement on this site is sourced to official FDA or government materials.

We never sell

BPC157.now does not sell, prescribe, dispense, ship, or facilitate the purchase of BPC-157 or any related product. This is a firm editorial policy, not just a legal disclaimer. If a reader wants to obtain BPC-157, this is not the site for that — and we will not link them elsewhere to do so.

Plain language

FDA regulatory documents are technical by design. Our job is to translate them accurately and accessibly — without dumbing down the meaning, adding spin, or importing wishful framing from either the pro-access or anti-access side of the debate.

Corrections policy

If we publish something factually incorrect, we correct it promptly and transparently. Corrections appear at the top of the affected article with a date. We do not silently rewrite history.

Questions about our coverage?

Media inquiries, editorial feedback, and corrections can be sent to our contact page. We read everything.

Contact usRead our coverage
Free Updates

Get updates when we publish

Free plain-language summaries of FDA materials — delivered when they matter.

BPC157.now does not sell, prescribe, or dispense BPC-157. Informational only.

Get Free BPC-157 Updates